Company Overview
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Why Investors Should Care
Revenue has grown at a 32.0% CAGR over the past five years.
Operating margin of 27.1% supports profitability.
Recent Developments
- Dec 2025 Revenue of $170.44M (+104.5% YoY); net profit $-193.88M.
- Trailing 12 Months Year-on-year growth — revenue +405.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 32.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 32.01% |
| 1 Year: | 405.70% |
Stock Price Performance
| 1 Year: | +0.11% |
| 6 Months: | +3.35% |
| 3 Months: | +47.04% |
| 1 Month: | -20.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.43 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 32.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 44.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RGNX REGENXBIO Inc. R2KR3KPHARMA | 8.94 | -2.37 | $590.16M | 0.00% | -48.13% | -137.63% | 32.01% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 455.00K | 6.56M | 1.34M | 2.04M | 132.39M | 40.03M | 5.31M | 40.78M | 884.00K | 7.88M | 14.70M | 11.77M | 17.64M | 16.57M | 98.91M | 21.45M | 18.88M | 22.04M | 30.77M | 22.22M | 32.65M | 26.51M | 19.14M | 19.98M | 28.91M | 15.62M | 22.30M | 24.20M | 89.01M | 21.36M | 29.73M | 6.39M | 108.02M |
| Operating Income | -6.30M | -7.35M | - | -11.25M | -14.95M | -18.67M | - | -22.92M | -15.06M | -21.31M | - | 102.03M | 6.35M | -22.73M | - | -35.91M | -36.87M | -35.90M | - | -37.70M | -41.83M | 13.95M | - | -44.04M | -52.23M | -57.35M | -71.53M | -62.53M | -71.05M | -66.16M | -73.11M | -64.96M | -63.86M | -56.04M | -62.08M | 12.13M | -63.28M | -52.41M | -83.36M | 29.26M |
| Net Income | -6.29M | -7.33M | -5.18M | -10.77M | -14.44M | -18.15M | -19.61M | -21.99M | -14.47M | -20.71M | -16.00M | 104.24M | 10.59M | -19.20M | 4.31M | -32.23M | -1.46M | -34.58M | -26.46M | -40.04M | -33.76M | 8.79M | -46.24M | -50.14M | -57.64M | -58.41M | -76.72M | -68.18M | -75.48M | -66.68M | -72.06M | -61.87M | -63.33M | -52.99M | -59.60M | 6.08M | -70.87M | -61.94M | -90.05M | 22.71M |
| Diluted EPS | - | - | - | - | - | - | - | -0.82 | -0.47 | -0.67 | -0.51 | 3.04 | 0.30 | -0.56 | 0.11 | -0.89 | -0.04 | -0.94 | -0.72 | -1.08 | -0.91 | 0.23 | -1.24 | - | -1.36 | -1.37 | -1.79 | -1.58 | -1.75 | -1.53 | -1.66 | -1.41 | -1.38 | -1.05 | -1.17 | 0.12 | -1.38 | -1.20 | -1.72 | 0.43 |
| R&D Expense | 4.01M | 5.66M | 4.81M | 6.18M | 10.68M | 12.56M | 16.06M | 16.62M | 13.92M | 12.52M | 14.17M | 19.55M | 21.49M | 18.51M | 24.33M | 25.20M | 29.48M | 35.69M | 33.81M | 37.03M | 38.11M | 43.97M | 47.18M | 39.72M | 45.88M | 47.85M | 55.63M | 61.01M | 63.31M | 58.52M | 59.89M | 58.18M | 54.84M | 48.87M | 54.43M | 53.09M | 59.50M | 56.10M | 57.34M | 56.09M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.09M | 6.12M | 7.59M | 4.59M | 10.39M | 218.50M | 35.23M | 154.57M | 470.35M | 112.72M | 90.24M | 83.33M | 170.44M |
| Operating Income | -4.78M | -3.68M | -23.14M | -65.34M | -75.89M | 88.10M | -149.00M | -119.23M | 159.98M | -262.88M | -268.13M | -233.35M | -161.20M |
| Net Income | -5.39M | -4.00M | -22.81M | -62.97M | -73.17M | 99.94M | -94.73M | -111.25M | 127.84M | -280.32M | -263.49M | -227.10M | -193.88M |
| Diluted EPS | - | - | - | -2.38 | -2.45 | 2.73 | -2.58 | -2.98 | 2.91 | -6.50 | -6.02 | -4.59 | -3.76 |
| R&D Expense | 5.05M | 4.96M | 17.28M | 45.48M | 57.22M | 83.87M | 124.19M | 166.29M | 181.44M | 242.45M | 232.27M | 208.52M | 228.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 3.49M | 221.38M | 172.73M | 198.68M | 543.81M | 497.91M | 708.16M | 1.11B | 833.27M | 573.97M | 465.99M | 453.03M |
| Total Equity | -8.11M | -13.92M | -18.29M | 216.81M | 161.74M | 183.03M | 508.85M | 450.20M | 377.75M | 764.30M | 516.20M | 311.74M | 259.65M | 102.73M |
| Cash & Equivalents | 2.17M | 1.12M | 1.12M | 54.12M | 24.84M | 46.66M | 75.56M | 69.51M | 338.43M | 345.21M | 96.95M | 34.52M | 57.53M | 34.47M |
| Total Liabilities | - | - | 9.19M | 4.57M | 10.99M | 15.65M | 34.97M | 47.71M | 330.41M | 349.61M | 317.07M | 262.23M | 206.34M | 350.30M |
| Current Liabilities | - | - | 9.19M | 4.34M | 9.67M | 14.44M | 22.18M | 33.68M | 81.45M | 130.47M | 130.43M | 130.27M | 103.19M | 118.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -48.56M | -57.99M | 104.65M | -107.70M | -54.06M | 218.88M | -207.49M | -218.41M | -173.12M | -123.96M |
| Investing Cash Flow | - | 19.39M | -4.79M | -279.36M | 93.56M | 122.76M | -406.64M | -11.93M | 190.94M | 103.45M | -15.87M |
| Financing Cash Flow | - | 119.00K | 84.60M | 204.44M | 8.38M | 200.21M | 195.25M | -28.84M | -34.97M | 92.68M | 116.77M |
| Capital Expenditure | -522.00K | -8.15M | -7.16M | -13.28M | -11.72M | -26.87M | -84.17M | -30.72M | -9.96M | -2.44M | -2.41M |
| Free Cash Flow | - | -56.71M | -65.15M | 91.37M | -119.42M | -80.93M | 134.70M | -238.21M | -228.37M | -175.56M | -126.38M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -78.5% | -60.2% | -304.9% | -1,423.8% | -730.2% | 40.3% | -422.9% | -77.1% | 34.0% | -233.2% | -297.1% | -280.0% | -94.6% |
| Net Margin % | -88.5% | -65.4% | -300.6% | -1,372.1% | -704.0% | 45.7% | -268.9% | -72.0% | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% |
| ROE % | 38.7% | 21.9% | -10.5% | -38.9% | -40.0% | 19.6% | -21.0% | -29.5% | 16.7% | -54.3% | -84.5% | -87.5% | -188.7% |
| ROCE % | - | 64.6% | -10.7% | -40.1% | -41.2% | 16.9% | -32.1% | -19.0% | 16.3% | -37.4% | -60.4% | -64.3% | -48.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.69% | 6.40M | $61.80M |
| 2 | Redmile Group, LLC | 6.62% | 4.37M | $42.20M |
| 3 | State Street Corporation | 4.50% | 2.97M | $28.70M |
| 4 | JPMORGAN CHASE & CO | 3.35% | 2.21M | $21.39M |
| 5 | Vanguard Capital Management LLC | 3.19% | 2.11M | $20.36M |
| 6 | Morgan Stanley | 2.96% | 1.95M | $18.87M |
| 7 | Goldman Sachs Group Inc | 2.15% | 1.42M | $13.73M |
| 8 | AQR Capital Management, LLC | 2.09% | 1.38M | $13.31M |
| 9 | Vanguard Portfolio Management LLC | 2.05% | 1.36M | $13.09M |
| 10 | Marshall Wace LLP | 1.95% | 1.28M | $12.41M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RGNX
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
Regenxbio Inc. (NASDAQ:RGNX) suffered another setback in its effort to bring RGX-121 to patients with Hunter syndrome. The FDA placed the experimental gene therapy on clinical hold after spinal scans identified abnormalities in five treated…
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene t…
Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street
Clear Street said the FDA decision would significantly delay Regenxbio’s resubmission of its application and a potential voucher that could bring in additional cash.
RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy
BofA called the clinical hold on RGX-121 disappointing and a reversal of July’s progress but kept a $15 price target on the stock.
Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling
Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company’s investigational therapy for Hunter syndome.
Why Did RGNX Stock Crash Today?
Regenxbio said the FDA has placed a clinical hold on its Hunter syndrome therapy after the discovery of unusual spine MRI findings in five participants in a study.
RGNX — Frequently Asked Questions
What is the current share price of REGENXBIO Inc. (RGNX)?
As of 2026-09-07 16:24 PDT, REGENXBIO Inc. (RGNX) trades at $8.94 on NasdaqGS. Its 52-week range is $5.65 to $15.98.
What is the market capitalisation of RGNX?
REGENXBIO Inc. (RGNX) has a market capitalisation of $590.16M on NasdaqGS.
What is the P/E ratio of RGNX?
RGNX trades at a trailing price-to-earnings (P/E) ratio of -2.37. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 8.09.
What is the return on equity (ROE) of RGNX?
RGNX has a return on equity (ROE) of -137.63%. Its return on capital employed (ROCE) is -48.13%.
Is RGNX a good stock to buy?
This page provides a data-driven analysis of REGENXBIO Inc. (RGNX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.